NCAM1 (Neural cell adhesion molecule 1)

In summary, this study illustrates that neoplastic T cells can show an NK-like immunophenotype. Features useful for supporting T-lineage in this context include cytoplasmic CD3 expression assessed using a T-cell-specific CD3 antibody, clonal TCR gene rearrangement, BCL11B expression, and detection of TCRαβ, TCRγδ, or TRBC by immunohistochemistry.

Since cases of early-stage gallbladder NETs are rare, their clinical behavior and long-term prognosis remain poorly understood. This case underscores the need for continued case accumulation and careful postoperative follow-up to establish appropriate management strategies for this rare entity.

This case underscores the need for clinical awareness of post-vaccination immunologic phenomena that may mimic plasma cell neoplasm. Recognition of such transient aberrancies can prevent unnecessary invasive investigations and broaden understanding of vaccine-induced immune dynamics.

Early detection and surgical intervention are critical for improving outcomes in gallbladder SCNEC associated with chronic inflammation.

All together these data show that OCs negatively affect the NK cell cytotoxic activity, allowing the growth of NSCLC CSCs. Our findings reveal a previously unrecognized role of OCs in modulating the immune microenvironment by dampening NK cell function.

Given the clinical presentation, anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was initially suspected, and the patient was treated with intravenous methylprednisolone and intravenous immunoglobulin, resulting in significant improvement...The clinical presentation and paraneoplastic association with teratoma closely resemble anti-NMDAR encephalitis, suggesting that anti-NCAM1 antibodies may define a novel form of AE with psychotic manifestations. Further research is needed to clarify their role in neuroinflammatory disorders.

We identified a feasible method to activate CD56+ cells and evaluate the safety of their infusion in patients. Despite the value of activating CD56+ cells with IL-15, further studies with larger sample sizes are needed to confirm and validate the current hypothesi (registration number: IRCT20230801058996N2).

Additional surgery confirmed no residual tumor or lymph node metastasis. Given the rarity of amphicrine carcinoma and the limited understanding of its clinical behavior, further research is necessary to determine its prognosis and optimal management strategies.

We developed and validated a robust ML-driven prognostic model based on peripheral blood lymphocyte subsets. This model, demonstrating superior prognostic value over conventional inflammatory markers, provides a novel and practical tool for personalized risk assessment in OS, potentially guiding more tailored treatment strategies.

As a risk factor, RAB7A relating to poor prognosis was identified in our study, and was a potential target for therapeutic agents such as PLX4720 and PD-0325901, while OXSM was the opposite. The 5-DRGs prognostic model can be used to assess the prognosis of patients with CC, and reflect the characteristics of their immune microenvironment. With RAB7A and OXSM as key determinants, this model provides a clinically applicable framework for risk stratification and personalized treatment guidance.

This represents the first reported case of testicular MST with MRI findings, and its distinctive imaging features correlate with the tumor's unique histological structure. In this study, we comprehensively analyzed the clinical, radiological, histological, and immunohistochemical characteristics of this case and compared them with previously documented features in the literature, aiming to enhance the understanding of this rare entity and facilitate accurate diagnosis.

Here, we found that exosomes secreted by lung cancer cells that had acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance and undergone epithelial-mesenchymal transition (osimertinib- and WZ4002-resistant H1975) exhibited enhanced brain-specific distribution and a concomitant increase in BrM compared with exosomes from parental H1975 cells. Clinically, exosomal L1CAM demonstrated diagnostic potential for BrM (area under the curve [AUC] = 0.80), and a combined exosomal L1CAM/ITGB3 panel significantly improved diagnostic accuracy (AUC = 0.98). Collectively, these findings identify exosomal L1CAM as a key regulator of brain-specific metastasis and support the clinical utility of the L1CAM/ITGB3 panel as a noninvasive biomarker for BrM in lung cancer.